fbpx

Bristol-Myers Squibb (BMY) Delay of Drug Approval Securities Complaint

December 10, 2021

Bristol-Myers Squibb Co. filed an S-4 Registration Statement for its November 2019 acquisition of Celgene Corporation. The complaint for this class action alleges that this S-4 contained untrue statements and omitted important information, because it did not disclose that Bristol-Myers was deliberately slow-walking approval of a drug. The slowdown would mean that certain milestones in the acquisition terms would not be met, which would thus save the company the expense of certain Contingent Value Rights (CVRs) offered as part of the acquisition deal.

Case Event File: Bristol-Myers Squibb (BMY) Delay of Drug Approval Securities Complaint

Related to: Bristol-Myers Squibb (BMY) Delay of Drug Approval Securities Class Action